Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway
Authors:
- 16 October 2021
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 89 (1) , 31-40
Abstract
Background Osteosarcoma is a prevalent type of bone tumor in children and adolescents, with limited treatment and poor prognosis. Abemaciclib, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), is approved for the treatment of advanced breast cancer as single agent therapy and is currently under investigation in clinical trials for the treatment of several solid tumors. Methods The efficacy of abemaciclib was determined using osteosarcoma cellular assays and xenograft mouse model. The combination studies were performed based on the Chou-Talalay method. Immunoblotting analysis was performed to determine the underlying mechanisms of abemaciclib in osteosarcoma cell lines. Results Abemaciclib potently inhibits growth, anchorage-independent colony formation and survival of a panel of osteosarcoma cell lines, with IC50 range from 90 nM to >20 μM. In addition, the combination of abemaciclib and doxorubicin is synergistic and antagonistic in abemaciclib-sensitive (IC50 1 μM), respectively. Abemaciclib inhibits tumor formation and growth in a dose-dependent manner without causing significant drug toxicity in mice. The combination of abemaciclib and doxorubicin results in much greater efficacy than doxorubicin alone in inhibiting tumor growth throughout the whole treatment duration. Abemaciclib acts on osteosarcoma via suppressing CDK4/6-Cyclin D-Rb pathway. Conclusions Our pre-clinical evidence provides a rationale of initializing clinical trial of investigating the efficacy of abemaciclib in combination with doxorubicin in osteosarcoma patients. Our work also highlights the therapeutic value of CDK4/6 inhibition in osteosarcoma with proper function of Rb.Keywords
Funding Information
- Hubei University of Medicine (20170616)
This publication has 33 references indexed in Scilit:
- Targeting CDK4 and CDK6: From Discovery to TherapyCancer Discovery, 2016
- Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase InhibitorJAMA Oncology, 2016
- Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentClinical Cancer Research, 2015
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency ModelComputational and Structural Biotechnology Journal, 2015
- The Soft Agar Colony Formation AssayJournal of Visualized Experiments, 2014
- Western blot: Technique, theory and trouble shootingNorth American Journal of Medical Sciences, 2014
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cellsNeuro-Oncology, 2012
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapyCell Cycle, 2012
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Different effects of ribosome biogenesis inhibition on cell proliferation in retinoblastoma protein- and p53-deficient and proficient human osteosarcoma cell linesCell Proliferation, 2007